Date de publication
Langue de la ressource
Texte disponible en version intégrale
Open Access / OK to Reproduce
Évalué par des pairs
Did pandemic disruptions in filled buprenorphine and extended-release naltrexone prescriptions for opioid use disorder (OUD) differ by race and ethnicity or insurance status and payer type?
Constatations/points à retenir
These findings suggest that the COVID-19 pandemic may have been associated with worsened disparities in filled buprenorphine and naltrexone prescriptions for OUD among members of racial and ethnic minority groups compared with White patients.
La conception ou méthodologie de recherche
Cross-sectional study of 92% of US retail pharmacy claims of buprenorphine among 1 556 860 individuals and extended-release naltrexone among 127 506 individuals for OUD from May 2019 to June 2021